Makes one wonder of those people discharged had really recovered, because if they had their antibodies should have fought it. The reports of the turning people away and sending home from hospitals were true

Up to 10 percent of recovered coronavirus patients test positive again, report says.

Misleading headline they should have stated in China

As many as 10% of recovered coronavirus patients in China tested positive again after being discharged from the hospital, according to a report.

Doctors on the front lines of the outbreak in Wuhan, China — where the virus emerged — reported that between 3 and 10% of cured patients became reinfected with the illness, though it’s unclear whether they were contagious the second time, the South China Morning Post reported.

Tongji Hospital, which identified the first COVID-19 case, confirmed that five of 145 patients — a little over 3% — tested positive again in nucleic acid tests, according to state broadcaster CCTV.

https://www.foxnews.com/health/up-to-10-percent-of-recovered-coronavirus-patients-test-positive-again-report-says

New Jersey doctor gives update on use of hydroxychloroquine, remdesivir on coronavirus patients

—The chief physician executive at Hackensack Meridian Health in New Jersey discussed on “Fox & Friends” how drugs meant to treat other conditions are now being used to help treat COVID-19 patients.

—“Anything that might work, it's nice to get out there,” Dr. Daniel Varga said on Monday. “It's great to use it in emergency situations, use it for compassionate use. Even better to get it out in clinical trials.”

—Varga made the comments responding to a report where two coronavirus patients in New York City were moved out of the intensive care unit after taking an experimental drug typically used to treat HIV and breast cancer. The patients went from being on ventilators in the ICU to a regular hospital in a matter of days, The Daily Mail reported. Studies reportedly suggest the drug, leronlimab, calms the overly aggressive immune response that could lead to pneumonia and even death.

—“I don't know the drug personally, but the studies we're seeing is that, like several drugs we’re trying to use right now in COVID-19, it works predominantly by toning down the immune response that the virus participates in the lung so that the lung doesn't get injured,” Varga said.

—On Monday, Dr. Varga described “three big buckets of clinical innovation” during the coronavirus outbreak.

—He said the first bucket is figuring out how to optimize standard care.

—“One of the things we’re seeing in people who have to get ventilated because of COVID-19 is this use of what’s known as prone ventilation, where you actually lay the patient on their belly while they are ventilated,” Varga said. “What it tends to do is lets the lungs expand more easily so you can get more oxygen down into the lungs and that's been a really big asset in trying to get these folks through their lung injury.”

—He noted that the second bucket is clinical trials.

—“We’re doing clinical trials right now with some antiviral drugs,” Varga said. “The most common one is remdesivir. We’re using that for both moderate and severe patients. We have enrolled patients in both of those trials. Looking at some other antiviral drugs as well.”

—In a press conference earlier this month, President Donald Trump and Food and Drug Administration (FDA) Commissioner Dr. Stephen Hahn described several approaches under testing, including remdesivir, which is being tried in at least five separate experiments, and chloroquine as well as hydroxychloroquine, drugs used to treat malaria.

—Developed by Gilead Sciences, remdesivir is described as an “investigational broad-spectrum antiviral treatment.” Previously, remdesivir was used to treat humans with Ebola.

—When host Brian Kilmeade asked Varga how coronavirus patients are responding to remdesivir, he said: “It’s hard to say.”

—“We’ve had some folks who’ve been on remdesivir who’ve done well and gone home,” Varga explained. “We have folks who are on it right now that are still intubated and in the ICU.”

—Chloroquine and the similar drug, hydroxychloroquine, have shown encouraging signs in small, early tests against the novel coronavirus, but they have yet to be studied during a controlled clinical trial.

—President Trump has spoken out about the importance of trying new treatments in hopes that we can learn where there's room for optimism and where there is not. He has touted the drugs used in malaria cases as a possible response to the coronavirus and now the FDA put in place an emergency use authorization to try these drugs despite clear evidence of their effectiveness.

—Dr. Oz gives update on clinical trials for drugs to treat COVID-19Video

“We are using hydroxychloroquine as an off-label use,” Varga said on Monday. “We use it for our intubated patients for the most part. We’re also using it for some of our nursing home patients because that's a group that you don't want to get sick, don't want to it to spread because they're so vulnerable.”

—“And the other trial that we are looking at right now that we hope to get launched later this week, we’ve actually had it fast-tracked up until now, is actually using hydroxychloroquine for what we call chemoprophylaxis or prevention for front-line caregivers,” he added.

—Chemoprophylaxis refers to the administration of a medication to prevent the development of a disease, according to Medicinenet

—Varga went on to say that there are currently 1,400 coronavirus patients in Hackensack Meridian Health facilities, with more than 300 in the ICU and more than 300 on ventilators.

—“We’re probably using the hydroxychloroquine recipe in some way shape or form in about three-quarters of our patients right now,” Varga said.

https://www.foxnews.com/media/coronavirus-patients-new-jersey-hydrocholoroquine-drug

either the article is wrong about 2018, or China has been trying to release a mass bioweapon since 2018 and before

Suspected SARS Virus And Flu Samples Found In Chinese Scientists’ Luggage Arriving In The U.S.: REPORT

Samples of the suspected SARS virus and influenza were found in Chinese scientists’ luggage arriving in the U.S., according to an unclassified FBI tactical intelligence report obtained by Yahoo News.

In November 2018, U.S. Customs and Border Protection agents at Detroit Metro Airport stopped a Chinese biologist who was carrying three vials labeled “Antibodies” in his luggage. The biologist said a colleague in China “had asked him to deliver the vials to a researcher at a U.S. institute. After examining the vials, however, customs agents came to an alarming conclusion,” Yahoo reported.

“Inspection of the writing on the vials and the stated recipient led inspection personnel to believe the materials contained within the vials may be viable Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) materials,” the report said.

The report, written by the Chemical and Biological Intelligence Unit of the FBI’s Weapons of Mass Destruction Directorate (WMDD), does not give the name of the Chinese scientist carrying the suspected SARS and MERS samples, or the intended recipient in the U.S. But the FBI concluded that the incident, and two other cases cited in the report, were part of an alarming pattern.

“The Weapons of Mass Destruction Directorate assesses foreign scientific researchers who transport undeclared and undocumented biological materials into the United States in their personal carry-on and/or checked luggage almost certainly present a US biosecurity risk,” reads the report. “The WMDD makes this assessment with high confidence based on liaison reporting with direct access.”

The report, which came out more than two months before the World Health Organization learned of a cluster of pneumonia cases in Wuhan that turned out to be COVID-19, appears to be part of a larger FBI concern about China’s involvement with scientific research in the U.S. While the report refers broadly to foreign researchers, all three cases cited involve Chinese nationals.

There have been numerous reports that the coronavirus may have emerged from a lab in Wuhan, China. In February, the Chinese Ministry of Science and Technology put out a directive titled: “Instructions on strengthening biosecurity management in microbiology labs that handle advanced viruses like the novel coronavirus.”

It turns out that in all of China there is only one such lab, the New York Post wrote. “And this one is located in the Chinese city of Wuhan that just happens to be . . . the epicenter of the epidemic.”

That’s right. China’s only Level 4 microbiology lab that is equipped to handle deadly coronaviruses, called the National Biosafety Laboratory, is part of the Wuhan Institute of Virology.

What’s more, the People’s Liberation Army’s top expert in biological warfare, a Maj. Gen. Chen Wei, was dispatched to Wuhan at the end of January to help with the effort to contain the outbreak.

According to the PLA Daily, Gen. Chen has been researching coronaviruses since the SARS outbreak of 2003, as well as Ebola and anthrax. This would not be her first trip to the Wuhan Institute of Virology either, since it is one of only two bioweapons research labs in all of China.

https://www.thegatewaypundit.com/2020/03/suspected-sars-virus-and-flu-samples-found-in-chinese-scientists-luggage-arriving-in-the-u-s-report/